USA > Switzerland based Novartis is set to acquire USA based AveXis Inc. for $8.7 billion

Novartis logo To transform care in SMA and expand its position as a gene therapy and Neuroscience leader, Novartis is set to acquire AveXis Inc. for $8.7 billion. AVXS-101, AveXis lead product candidate, has the potential to be the first ever one time gene replacement therapy for spinal muscular atrophy (SMA). SMA is a disease that results in either early death or More …

SWITZERLAND > UK based GSK (GlaxoSmithKline) is set to buyout Novartis’ 36.5% stake in the Consumer Healthcare Joint Venture for $13 billion

gsk logo UK based GSK is all set to buyout Switzerland based Novartis stake in the Consumer Healthcare Joint venture for $13 billion. Formed as part of the three part transaction between GSK and Novartis in 2014, Consumer Healthcare Joint Venture’s 100% ownership by GSK enables GSK shareholders to capture full value of future performance. According to Emma Walmsley, Chief Executive Officer, More …

SWITZERLAND > Sun Pharma to acquire Odomzo from Novartis for $175Mn

Sun_Pharma_Logo.svg Indian Drug Company, Sun Pharmaceutical to acquire oncology product, Odomzo, from Novartis for $175Mn. The deal is subjected to some customary closing conditions. USFDA in July 2015 approved Odomzo. It is used for the treatment of adult patients with locally advanced basal cell carcinoma. After the deal was struck Kirti Ganorkar, Global Head Business Development at Sun Pharma said, “Odomzo gives More …